MY156754A - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners - Google Patents
Compounds and methods for inhibiting the interaction of bcl proteins with binding partnersInfo
- Publication number
- MY156754A MY156754A MYPI20091840A MYPI20091840A MY156754A MY 156754 A MY156754 A MY 156754A MY PI20091840 A MYPI20091840 A MY PI20091840A MY PI20091840 A MYPI20091840 A MY PI20091840A MY 156754 A MY156754 A MY 156754A
- Authority
- MY
- Malaysia
- Prior art keywords
- compounds
- inhibiting
- interaction
- binding partners
- methods
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/600,332 US7842815B2 (en) | 2004-06-17 | 2006-11-15 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY156754A true MY156754A (en) | 2016-03-31 |
Family
ID=39064388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20091840A MY156754A (en) | 2006-11-15 | 2007-11-14 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7842815B2 (OSRAM) |
| EP (1) | EP2094673B1 (OSRAM) |
| JP (2) | JP2010510214A (OSRAM) |
| KR (1) | KR101530721B1 (OSRAM) |
| CN (1) | CN101583606B (OSRAM) |
| AU (1) | AU2007319848B2 (OSRAM) |
| BR (1) | BRPI0718606A2 (OSRAM) |
| CA (1) | CA2669596C (OSRAM) |
| EC (1) | ECSP099398A (OSRAM) |
| ES (1) | ES2537762T3 (OSRAM) |
| GT (1) | GT200900123A (OSRAM) |
| IL (1) | IL198597A (OSRAM) |
| MA (1) | MA31067B1 (OSRAM) |
| MX (1) | MX2009005184A (OSRAM) |
| MY (1) | MY156754A (OSRAM) |
| NO (1) | NO20092306L (OSRAM) |
| NZ (1) | NZ577243A (OSRAM) |
| RU (1) | RU2449996C2 (OSRAM) |
| TN (1) | TN2009000182A1 (OSRAM) |
| WO (1) | WO2008060569A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2118123B1 (en) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP3159352B1 (en) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
| WO2009099677A2 (en) * | 2008-02-08 | 2009-08-13 | Aileron Therapeutics, Inc. | Therapeutic peptidomimetic macrocycles |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| EP2812695A4 (en) | 2012-02-06 | 2015-12-02 | Discoverx Corp | DETECTION OF INTRA-CELLULAR BINDING EVENTS BY MEASUREMENT OF THE PROTEIN FILL |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
| US20160068463A1 (en) | 2012-11-14 | 2016-03-10 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| WO2017172826A1 (en) | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| HRP20221385T1 (hr) * | 2017-04-05 | 2023-01-06 | President And Fellows Of Harvard College | Makrociklički spoj i njegova uporaba |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| HU222234B1 (hu) | 1990-05-18 | 2003-05-28 | Aventis Pharma Deutschland Gmbh. | Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására |
| US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| DK0623615T3 (da) * | 1993-05-01 | 1999-12-13 | Merck Patent Gmbh | Adhæsionsreceptor-antagonister |
| DE69426604T2 (de) | 1993-11-24 | 2001-05-10 | Dupont Pharmaceuticals Co., Wilmington | Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten |
| EP0749428B1 (en) | 1994-03-09 | 1998-07-29 | Pfizer Inc. | Isoxazoline compounds as inhibitors of tnf release |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| EP0934265B1 (en) | 1996-08-16 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| WO1998050031A1 (en) | 1997-05-07 | 1998-11-12 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU7105800A (en) | 1999-09-01 | 2001-03-26 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| KR20040108528A (ko) | 2001-05-30 | 2004-12-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｂｃｌ2 군 단백질의 소분자 길항제 |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| US20060020004A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
| US7851637B2 (en) | 2004-06-17 | 2010-12-14 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
-
2006
- 2006-11-15 US US11/600,332 patent/US7842815B2/en not_active Expired - Fee Related
-
2007
- 2007-11-14 MY MYPI20091840A patent/MY156754A/en unknown
- 2007-11-14 AU AU2007319848A patent/AU2007319848B2/en not_active Ceased
- 2007-11-14 NZ NZ577243A patent/NZ577243A/en not_active IP Right Cessation
- 2007-11-14 WO PCT/US2007/023941 patent/WO2008060569A1/en not_active Ceased
- 2007-11-14 CA CA2669596A patent/CA2669596C/en not_active Expired - Fee Related
- 2007-11-14 JP JP2009537198A patent/JP2010510214A/ja active Pending
- 2007-11-14 MX MX2009005184A patent/MX2009005184A/es active IP Right Grant
- 2007-11-14 CN CN200780049702.7A patent/CN101583606B/zh not_active Expired - Fee Related
- 2007-11-14 RU RU2009121808/04A patent/RU2449996C2/ru not_active IP Right Cessation
- 2007-11-14 BR BRPI0718606-1A patent/BRPI0718606A2/pt not_active IP Right Cessation
- 2007-11-14 KR KR1020097012239A patent/KR101530721B1/ko not_active Expired - Fee Related
- 2007-11-14 ES ES07840052.0T patent/ES2537762T3/es active Active
- 2007-11-14 EP EP07840052.0A patent/EP2094673B1/en active Active
-
2009
- 2009-05-06 IL IL198597A patent/IL198597A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000182A patent/TN2009000182A1/fr unknown
- 2009-05-12 GT GT200900123A patent/GT200900123A/es unknown
- 2009-06-09 EC EC2009009398A patent/ECSP099398A/es unknown
- 2009-06-10 MA MA31972A patent/MA31067B1/fr unknown
- 2009-06-15 NO NO20092306A patent/NO20092306L/no not_active Application Discontinuation
-
2010
- 2010-11-30 US US12/956,969 patent/US8461191B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 JP JP2013230960A patent/JP2014055156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010510214A (ja) | 2010-04-02 |
| EP2094673A1 (en) | 2009-09-02 |
| US8461191B2 (en) | 2013-06-11 |
| AU2007319848A1 (en) | 2008-05-22 |
| WO2008060569A1 (en) | 2008-05-22 |
| MA31067B1 (fr) | 2010-01-04 |
| AU2007319848B2 (en) | 2012-05-03 |
| US20080306127A9 (en) | 2008-12-11 |
| EP2094673B1 (en) | 2015-04-08 |
| KR101530721B1 (ko) | 2015-06-22 |
| US7842815B2 (en) | 2010-11-30 |
| US20070161690A1 (en) | 2007-07-12 |
| RU2449996C2 (ru) | 2012-05-10 |
| ES2537762T3 (es) | 2015-06-11 |
| CA2669596A1 (en) | 2008-05-22 |
| US20110160259A1 (en) | 2011-06-30 |
| NZ577243A (en) | 2011-12-22 |
| CN101583606A (zh) | 2009-11-18 |
| TN2009000182A1 (en) | 2010-10-18 |
| KR20090082284A (ko) | 2009-07-29 |
| GT200900123A (es) | 2011-09-02 |
| ECSP099398A (es) | 2009-07-31 |
| NO20092306L (no) | 2009-08-17 |
| JP2014055156A (ja) | 2014-03-27 |
| IL198597A (en) | 2014-03-31 |
| CA2669596C (en) | 2014-09-30 |
| IL198597A0 (en) | 2010-02-17 |
| BRPI0718606A2 (pt) | 2013-12-17 |
| MX2009005184A (es) | 2009-10-12 |
| HK1130057A1 (en) | 2009-12-18 |
| RU2009121808A (ru) | 2010-12-20 |
| CN101583606B (zh) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY156754A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| NO20070324L (no) | Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere | |
| JO2917B1 (en) | Compounds and methods to inhibit the interaction between BCL and binding partners | |
| TNSN08258A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| MX2010001565A (es) | Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90. | |
| MX2009008547A (es) | Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer. | |
| TW200738234A (en) | Triazole compounds that modulate HSP90 activity | |
| MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
| TW200637831A (en) | Triazole compounds that modulate Hsp90 activity | |
| SG10201407457UA (en) | Iap bir domain binding compounds | |
| WO2007139960A3 (en) | Compounds that modulate hsp90 activity and methods for identifying same | |
| WO2007139967A3 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2007139955A3 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2007139968A3 (en) | Triazole compounds that modulate hsp90 activity | |
| MX2007011859A (es) | Compuestos mejorados farmacocineticamente. | |
| MX2009008656A (es) | Anticuerpos contra erbb3 y usos de los mismos. | |
| TW200738683A (en) | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | |
| TN2010000169A1 (en) | Molecules and methods for modulating complement component | |
| MY145917A (en) | Biocide composition comprising pyrithione and pyrrole derivatives | |
| WO2007022947A3 (de) | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
| MY155908A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| TNSN06418A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| TW200621265A (en) | Composition for treating tumor and/or preventing tumor transfer and recurrence | |
| TW200800952A (en) | Biaryl compositions and methods for modulating a kinase cascade | |
| CY1115478T1 (el) | Ενωσεις τριαζολης που διαμορφωνουν δραση ηsρ90 |